Companies combine key capabilities to advance flow
cytometry as an essential companion diagnostic modality for cancer
and other diseases
FRANKLIN
LAKES, N.J., Aug. 9, 2022
/PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a
leading global medical technology company, today announced a
collaboration agreement with Labcorp (NYSE: LH), a leading global
life sciences company, creating a framework to develop,
manufacture, market and commercialize flow cytometry-based
companion diagnostics (CDx) intended to match patients with
life-changing treatments for cancer and other diseases.
The agreement creates a framework for BD and Labcorp Drug
Development to collaborate on flow cytometry-based CDx
opportunities with pharmaceutical partners. The two companies bring
together capabilities that comprise an end-to-end solution for CDx
development for the pharmaceutical industry. Their joint offering
ranges from exploratory panel development to U.S. Food and Drug
Administration (FDA) approval of diagnostic and IVD kit
manufacturing and distribution.
"Flow cytometry is a trusted and powerful tool for analyzing
cells to better understand disease, and it has tremendous untapped
potential as a companion diagnostic in oncology and other
therapeutic areas," said Dr. Bill
Hanlon, chief scientific officer of Labcorp Drug
Development. "This strategic collaboration with BD, a pioneer and
global leader in flow cytometry, is an exciting step toward
increasing adoption and ultimately bringing innovative new
companion diagnostics to market to help identify patients who could
benefit most from appropriate treatments."
Selecting the optimal first-line therapy for patients with
cancer by using companion diagnostics can be critical to ensuring
the best outcomes and time and cost savings. Today's companion
diagnostic tests commonly involve technologies such as
immunohistochemistry (IHC), fluorescence in situ hybridization
(FISH), polymerase chain reaction (PCR), next-generation sequencing
(NGS) and imaging. Flow cytometry is an emerging technology in the
field.
"In the companion diagnostic landscape, there is a clear and
urgent need for high sensitivity and multiplexing capabilities, and
that is where flow cytometry can help," said Puneet Sarin, president of BD Biosciences. "BD
and our dedicated CDx team are uniquely positioned to advance flow
cytometry as a companion diagnostic tool, and we are pleased to
join forces with Labcorp, a trusted global leader in diagnostic
testing and drug development, to pursue opportunities with the
pharmaceutical industry to develop new companion diagnostics that
can potentially improve patient outcomes and drive us forward in
advancing the world of health."
About BD
BD is one of the largest global medical
technology companies in the world and is advancing the world of
health™ by improving medical discovery, diagnostics and the
delivery of care. The company supports the heroes on the frontlines
of health care by developing innovative technology, services and
solutions that help advance both clinical therapy for patients and
clinical process for health care providers. BD and its 75,000
employees have a passion and commitment to help enhance the safety
and efficiency of clinicians' care delivery process, enable
laboratory scientists to accurately detect disease and advance
researchers' capabilities to develop the next generation of
diagnostics and therapeutics. BD has a presence in virtually every
country and partners with organizations around the world to address
some of the most challenging global health issues. By working in
close collaboration with customers, BD can help enhance outcomes,
lower costs, increase efficiencies, improve safety and expand
access to health care. For more information on BD, please visit
bd.com or connect with us on LinkedIn at
www.linkedin.com/company/bd1/ and Twitter @BDandCo.
Contacts:
|
|
Media:
|
Investors:
|
Troy Kirkpatrick
|
Francesca
DeMartino
|
VP, Public Relations
|
SVP, Head of Investor
Relations
|
858.617.2361
|
201.847.5743
|
troy.kirkpatrick@bd.com
|
francesca.demartino@bd.com
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/bd-labcorp-collaborate-to-develop-flow-cytometry-based-companion-diagnostics-for-matching-patients-with-treatments-301601797.html
SOURCE BD (Becton, Dickinson and Company)